Nivalis Therapeutics and Seattle's Alpine Immune Sciences to merge

Nivalis Therapeutics and Seattle's Alpine Immune Sciences to merge

BOULDER -- Nivalis Therapeutics, Inc. (NASDAQ: NVLS) and Seattle-based Alpine Immune Sciences, Inc., a privately-held biotechnology company developing novel therapies using its next-generation... Read More

Thursday April 20, 2017 0 comments Tags: Boulder, Nivalis Therapeutics, Alpine Immune Sciences, Howard Furst, Mitchell H. Gold

N30 Pharmaceuticals appoints Jon Congleton to be president and CEO

N30 Pharmaceuticals appoints Jon Congleton to be president and CEO

BOULDER - N30 Pharmaceuticals Inc. , a clinical-stage, biopharmaceutical company focused on development of therapies for cystic fibrosis, announced its board of directors has appointed Jon... Read More

By: InnovatioNews Tuesday December 23, 2014 0 comments Tags: Boulder, cystic fibrosis, Howard Furst, Jon Congleton, N30 Pharmaceuticals

N30 Pharma picks up $30M in mezzanine funding round to advance cystic fibrosis drug

N30 Pharma picks up $30M in mezzanine funding round to advance cystic fibrosis drug

BOULDER - N30 Pharmaceuticals Inc. , a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, announced it raised $30 million in a mezzanine... Read More

By: InnovatioNews Monday November 24, 2014 0 comments Tags: Boulder, cystic fibrosis, Deerfield Management, Howard Furst, Jennison Associates, N30 Pharmaceuticals, N91115, Sabby Management